|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 129.36 USD | +0.05% |
|
+0.75% | +48.31% |
Summary: Blueprint Medicines Corporation
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Highlights: Blueprint Medicines Corporation
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company is in a robust financial situation considering its net cash and margin position.
- For the past twelve months, EPS forecast has been revised upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses: Blueprint Medicines Corporation
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings Chart: Blueprint Medicines Corporation
Source: Surperformance
ESG chart: Blueprint Medicines Corporation
Source: MSCI
| Fundamentals (Composite) | Global Valuation (Composite) | Financial estimates revisions (Composite) | Capi.($) | ||
|---|---|---|---|---|---|
| - | - | 8.37B | |||
| 50.05B | |||||
| 29.87B | |||||
| 28.29B | |||||
| 27.7B | |||||
| 12.6B | |||||
| 11.88B | |||||
| 10.46B | |||||
| Average | 22.4B | ||||
| Weighted average by Cap. |
Investor (Composite)
-
Trader (Composite)
ESG MSCI
BB
Financials
Revenue growth
EPS growth
Capital Efficiency (Composite)
Net Margin
Financial Health (Composite)
-
Valuation
P/E
-
EV/Revenue
EV/EBITDA
-
PBR
Dividend Yield
Revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
Revenue revisions (1 month)
EPS revisions (1 year)
EPS revisions (4 months)
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (4 months)
Analysts' target price evolution (1 year)
Business Predictability
Surprise rates
Analysts' coverage
Analysts' recommendations divergence
Analysts' Target price divergence
Financial estimates divergence
ESG
Environment
Social
Governance
Controversy
Ethical controversies
Human rights controversies
Tax subsidies controversies
Sharia compliant
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- BPMC Stock
- Ratings Blueprint Medicines Corporation
Select your edition
All financial news and data tailored to specific country editions
